Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Science Applications International Corporation (SAIC) has granted $3.1m sub-contract to Pfenex to support the company for the development of scalable, cGMP ready production process for large scale production of full length Circumsporozoite protein (CSP) from Plasmodium falciparum.
Subscribe to our email newsletter
Pfenex is now set to start the process development activities with immediate action so as to offer materials to SAIC for ongoing pre-clinical studies.
The current contract is a result of successful pre-clinical studies performed utilizing the full length CSP antigen expressed in Pfenex Expression Technology.
CEO Bertrand Liang said they are pleased to be awarded this contract in support of DMID’s efforts to find an effective therapy for malaria.
"Pfenex Expression Technology has made the recombinant production of significant quantities of full length, soluble, active CSP antigen a reality, a complex protein that has previously been refractory to recombinant expression in other expression platforms" Liang said.